Avangio 400mg Injection

About

Avangio, containing the active ingredient likely to be Bevacizumab, is a sophisticated recombinant humanized monoclonal antibody engineered to specifically target and neutralize vascular endothelial growth factor (VEGF). VEGF is a crucial signaling protein that orchestrates angiogenesis, the process fundamental for the formation of new blood vessels. Malignant tumors exploit angiogenesis to develop a robust blood supply, which is indispensable for their rapid growth, metabolic demands, and metastatic spread. By binding to VEGF, Avangio effectively blocks its biological activity, thereby impeding the development of new blood vessels within the tumor microenvironment and compromising the integrity of existing tumor vasculature. This targeted approach deprives the tumor of essential nutrients and oxygen, leading to a significant suppression of tumor proliferation and progression. It is a vital component in the therapeutic regimen for several advanced cancers, often administered in conjunction with chemotherapy to optimize treatment efficacy and enhance patient survival.

Uses

• Metastatic colorectal cancer
• Non-small cell lung cancer
• Glioblastoma multiforme
• Metastatic renal cell carcinoma

Directions For Use

Administer intravenously by a healthcare professional. The dosage and infusion schedule are tailored to the patient's body weight and the specific cancer being treated.

Benefits

• Inhibits tumor angiogenesis
• Slows tumor progression
• Enhances efficacy of chemotherapy
• Improves overall survival in some cancers
• Reduces tumor vascularization
• Targets a critical growth pathway

Side Effects

• Hypertension
• Proteinuria
• Hemorrhage
• Thromboembolic events
• Gastrointestinal perforation
• Wound healing complications
• Fatigue
• Headache
• Diarrhea
• Nausea
• Vomiting
• Neutropenia

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake during cancer treatment.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm, including malformations and fetal growth restriction. Effective contraception is required during treatment and for 6 months after the last dose.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if Avangio is excreted in human milk. Potential for serious adverse reactions in breastfed infants.
• Liver - Use with caution in patients with pre-existing liver conditions. Liver function should be monitored regularly during treatment.
• Kidney - Use with caution in patients with pre-existing kidney conditions. Renal function should be monitored, especially for proteinuria.
• Lung - Use with caution in patients with a history of pulmonary hemorrhage or other lung conditions. Monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.